Lockheed Martin Investment Management Company Raised Bristol Myers Squibb (BMY) Stake by $4.32 Million

March 19, 2018 - By wolcottdaily

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It increased, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported. Albion Financial Grp Ut invested in 0.5% or 51,792 shares. Boys Arnold And Co Inc reported 0.11% in Bristol-Myers Squibb Company (NYSE:BMY). Bangor Bank holds 0.13% in Bristol-Myers Squibb Company (NYSE:BMY) or 10,259 shares. United Savings Bank Va reported 6,812 shares or 0.41% of all its holdings. Foundry Limited Liability Com reported 0.76% stake. Nelson Roberts Invest Advsr Ltd accumulated 87,325 shares. Wesbanco Natl Bank Inc reported 490,377 shares stake. Pacific Glob Invest invested in 12,670 shares or 0.18% of the stock. Baker Ellis Asset Management Ltd Liability Com accumulated 0.56% or 33,352 shares. Ubs Asset Americas owns 4.89M shares. Madrona Fin Ser Limited Liability Corp has invested 0.21% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Dubuque Bancorp & invested in 9,619 shares or 0.1% of the stock. Gfs Lc has invested 0.07% in Bristol-Myers Squibb Company (NYSE:BMY). New England Research & Mgmt, Illinois-based fund reported 24,617 shares. Evercore Wealth Mgmt Ltd Company accumulated 0.3% or 121,180 shares.

Since December 12, 2017, it had 1 insider purchase, and 1 sale for $85,985 activity. Lynch Thomas J. Jr. had sold 5,300 shares worth $335,172.

Lockheed Martin Investment Management Company increased its stake in Bristol Myers Squibb (BMY) by 242.91% based on its latest 2017Q3 regulatory filing with the SEC. Lockheed Martin Investment Management Company bought 68,500 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 96,700 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $6.16 million, up from 28,200 at the end of the previous reported quarter. Lockheed Martin Investment Management Company who had been investing in Bristol Myers Squibb for a number of months, seems to be bullish on the $107.64B market cap company. The stock decreased 1.01% or $0.67 during the last trading session, reaching $65.93. About 4.00 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since March 19, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Lockheed Martin Investment Management Company, which manages about $1.89 billion US Long portfolio, decreased its stake in Select Sector Spdr (XLF) by 151,398 shares to 4.33M shares, valued at $111.93 million in 2017Q3, according to the filing. It also reduced its holding in Select Sector Spdr (XLK) by 157,376 shares in the quarter, leaving it with 2.91 million shares, and cut its stake in Travelers Companies Ord (NYSE:TRV).

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 21 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 11 Hold. Therefore 33% are positive. Bristol-Myers Squibb Company had 76 analyst reports since July 28, 2015 according to SRatingsIntel. Credit Suisse maintained it with “Neutral” rating and $61 target in Friday, October 27 report. The stock has “Sell” rating by BMO Capital Markets on Monday, June 5. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Buy” rating by Jefferies on Friday, September 15. As per Monday, October 30, the company rating was upgraded by SunTrust. The stock has “Equal-Weight” rating by Barclays Capital on Friday, October 13. The company was maintained on Monday, May 9 by Credit Suisse. The stock has “Market Perform” rating by BMO Capital Markets on Monday, January 25. The firm has “Hold” rating given on Monday, July 10 by Cowen & Co. The company was maintained on Monday, October 16 by SunTrust. The firm has “Hold” rating given on Tuesday, June 14 by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.